Larazotide vs BPC-157 — Peptide Comparison

Larazotide vs BPC-157 — Peptide Comparison Larazotide vs BPC-157 — compare dosing, benefits, safety profiles, side effects, and how they stack. See which peptide is right for you. At a Glance Dose Range Larazotide 250 mcg–1000 mcg mcg BPC-157 250–500 mcg Frequency Once daily Administration Oral (capsule or tablet) Subcutaneous injection Cycle Length Ongoing/indefinite 4-6 weeks Onset Speed Moderate (1-2 weeks) Evidence Level Strong human trials (Phase 3 or FDA approved) Strong preclinical (extensive animal studies) Efficacy Intestinal Barrier Protection Celiac Disease Management Safety & Tolerability Primary Benefit Secondary Benefit Additional Benefit Technical Data Molecular Formula C34H59N9O12 Molecular Weight 785.9 g/mol Half-Life Unknown - acts primarily as local intestinal barrier regulator rather than systemic drug Bioavailability Orally administered; acts locally on intestinal epithelium with minimal systemic absorption CAS Number 206899-25-6 C62H98N16O22 1419.53 g/mol 4-6 hours ~100% (subcutaneous) 137525-51-0 Protocols standard 0.5 mg Three times daily (before meals) 12 weeks in trials; ongoing for symptom control Trial-established dose: in a Phase 2b randomized controlled trial in celiac disease, 0.5 mg three times daily met the primary endpoint with fewer symptoms vs placebo. Notably, the higher 1 mg and 2 mg doses showed no benefit over placebo, so 0.5 mg is the effective dose [6]. Taken before meals as a local intestinal tight-junction regulator [1]. starting 250 mcg 1-2 weeks A common starting amount in research practice, often injected near the injured area. BPC-157 has no human dose-finding trials, so doses come from animal studies and documented practice [1][2]. 250-500 mcg Twice daily Commonly used range for tissue and tendon recovery in research practice [1][3]. advanced 500 mcg 6-8 weeks Upper end used in practice for more demanding acute injuries [1][3]. Applications Managing celiac disease symptoms despite strict gluten avoidance Larazotide is particularly well-suited for individuals focused on managing celiac disease symptoms despite strict gluten avoidance. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Reducing accidental gluten exposure damage Larazotide is particularly well-suited for individuals focused on reducing accidental gluten exposure damage. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Restoring digestive comfort and nutrient absorption Larazotide is particularly well-suited for individuals focused on restoring digestive comfort and nutrient absorption. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Supporting intestinal healing and barrier function Larazotide is particularly well-suited for individuals focused on supporting intestinal healing and barrier function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Tendon and ligament injuries Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair Gut healing IBS, leaky gut, ulcers, inflammatory bowel conditions - derived from gastric juice, it has a natural affinity for digestive tissue Muscle injuries Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression Joint problems Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties Post-surgical recovery Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms Safety Profile Common Headache Nausea Abdominal Cramping Fatigue Uncommon Transient Diarrhea Serious Allergic Reaction Injection site redness Mild nausea Dizziness Hot/cold sensations Allergic reaction Research Status FDA Status Not FDA approved Safety Overview Larazotide (ALX-0061, AT-1001) is a synthetic tight-junction regulator that improved intestinal barrier function in Phase 2 celiac disease trials with favorable safety. The mechanism—zonula occludens-1 modulation—is specific to epithelial tight junctions without broad immunosuppression. Gastrointestinal side effects (nausea, diarrhea, abdominal pain) occur in 10-20% of patients but are typically mild and resolve with dose adjustment or continued exposure. FDA feedback on Phase 3 trials indicated efficacy trends but required additional manufacturing and clinical data before approval consideration. Contraindications xKnown hypersensitivity to larazotide or any component xSevere gastrointestinal obstruction xActive untreated infections (may require monitoring) xPregnancy and breastfeeding (limited safety data) Research compound BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. No FDA approval exists. Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions. xPregnancy xBreastfeeding xActive cancer xHistory of cancer Decision Guide Choose Larazotide if... Managing celiac disease symptoms despite strict gluten avoidance Reducing accidental gluten exposure damage Restoring digestive comfort and nutrient absorption Supporting intestinal healing and barrier function Choose BPC-157 if... Injury recovery Post-surgery healing Chronic pain management Gut health